Dr. Nataliya V. Uboha
Claim this profileUniversity of Wisconsin Carbone Cancer Center
Studies Uterine Tumors
Studies Stomach Cancer
21 reported clinical trials
54 drugs studied
About Nataliya V. Uboha
Education:
- Holds both an MD (Doctor of Medicine) and a PhD (Doctor of Philosophy), with unspecified fields of study.
Experience:
- Serves as an Associate Professor at the University of Wisconsin's Carbone Cancer Center.
- Leads the Early Phase Oncology Therapeutics Program at UWCCC.
- Recognized as a national expert in gastric cancer.
- Holds co-chair positions for both the ECOG-ACRIN Upper GI Working Group and the NCI Esophagogastric Taskforce.
- Actively involved in patient-centered care, emphasizing shared decision-making and comprehensive support in treatment plans.
Area of expertise
1Uterine Tumors
Stage IV
Stage III
HER2 positive
2Stomach Cancer
Stage IV
Stage III
HER2 negative
Affiliated Hospitals
Clinical Trials Nataliya V. Uboha is currently running
Chemotherapy + Radiotherapy
for Esophageal and Gastric Cancer
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
Recruiting2 awards Phase 320 criteria
Nivolumab + Standard Treatment
for Stomach and Esophageal Cancer
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting1 award Phase 2 & 320 criteria
More about Nataliya V. Uboha
Clinical Trial Related6 years of experience running clinical trials · Led 21 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Nataliya V. Uboha has experience with
- Olaparib
- Paclitaxel
- Nivolumab
- Oxaliplatin
- Gemcitabine
- Zimberelimab
Breakdown of trials Nataliya V. Uboha has run
Stomach Cancer
Esophageal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nataliya V. Uboha specialize in?
Nataliya V. Uboha focuses on Uterine Tumors and Stomach Cancer. In particular, much of their work with Uterine Tumors has involved Stage IV patients, or patients who are Stage III.
Is Nataliya V. Uboha currently recruiting for clinical trials?
Yes, Nataliya V. Uboha is currently recruiting for 11 clinical trials in Madison Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Nataliya V. Uboha has studied deeply?
Yes, Nataliya V. Uboha has studied treatments such as Olaparib, Paclitaxel, Nivolumab.
What is the best way to schedule an appointment with Nataliya V. Uboha?
Apply for one of the trials that Nataliya V. Uboha is conducting.
What is the office address of Nataliya V. Uboha?
The office of Nataliya V. Uboha is located at: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin 53792 United States. This is the address for their practice at the University of Wisconsin Carbone Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.